A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 2, 2010, Pages 158-166

  Osmancik, Pavel ^a   Jirmar, Radovan ^a   Hulikova, Katarina ^b   Peroutka, Zdenek ^b   Pompachova, Alexandra ^b   Motovska, Zuzana ^a   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute myocardial infarction; Cardiogenic shock; Clopidogrel; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; DOBUTAMINE; DOPAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORADRENALIN; PROTON PUMP INHIBITOR; UREA; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE HEART INFARCTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMODYNAMICS; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; ST SEGMENT ELEVATION; STENT THROMBOSIS; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CATECHOLAMINES; CELL ADHESION MOLECULES; DOWN-REGULATION; DRUG MONITORING; FEMALE; HEMODYNAMICS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER CIRCULATION; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; SHOCK, CARDIOGENIC; SPLANCHNIC CIRCULATION; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 76049120468     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22248     Document Type: Article

References (23)

1. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, Mckinlay SM, Lejemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625-634.
2. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, Urban P. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008;149:618-626.
3. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the european society of cardiology. Eur Heart J 2005;26:804-847.
4. Steinhubl SR, Berger PB, Mann JT, Fry ET, Delago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
5. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005;51:957-965.
6. Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 2008;19:551-554.
7. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98: 838-843.
8. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
9. Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996;22:1339-1344.
10. Schedel A, Schloss P, Kluter H, Bugert P. The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 2008;378:431-439.
11. Jakob SM, Parviainen I, Ruokonen E, Uusaro A, Takala J. Lack of effect of ranitidine on gastric luminal pH and mucosal PCO2 during the first day in the ICU. Acta Anaesthesiol Scand 2005;49:390-396.
12. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
13. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999;82:1145-1152.
14. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3: 85-92.
15. Dive A, Moulart M, Jonard P, Jamart J, Mahieu P. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Crit Care Med 1994;22:441-447.
16. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988;94:739-744.
17. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, Von Beckerath N, Schomig A, Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-316.
18. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
19. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
20. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-1563.
21. Cuisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, Lambert M, Juhan-Vague I, Alessi MC, Bonnet JL. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603.
22. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
23. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008;156: S23-S28.